21May 2024
Chemotherapy Monotherapy for Recurrent Cervical Cancer: Efficacy and Safety Study

Chemotherapy Monotherapy for Recurrent Cervical Cancer: Efficacy and Safety Study

A study investigated chemotherapy (CT) monotherapy's efficacy and safety in patients with recurrent intermediate/high-risk factors post-radical hysterectomy for stage IB-IIA cervical cancer. Sixty-six patients received CT exclusively, 42 in the intermediate-risk and 24 in the high-risk group. Treatment included paclitaxel and cisplatin for 4–6 cycles. The 3-year and 5-year relapse-free survival (RFS) rates were satisfactory, with no significant difference between risk groups. Recurrence rates were low in both groups. These findings suggest CT monotherapy post-hysterectomy provides favourable survival outcomes and tolerable adverse effects across risk categories.

  • #gynaecology - ivf

Like

Save

Share